NBIX:NASDAQ
Neurocrine Biosciences, Inc
$138.35
arrow_downward
-1.49%(-2.09) 1D
$138.35
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 29, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
$138.26
High
$141.07
Low
$136.31
Mkt. cap
14.06B
Avg. vol.
1.15M
Volume
1.50M
P/E ratio
20.28
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.38
Shares outstanding
101.65M
No. of employees
2K
Open
$138.26
High
$141.07
Low
$136.31
Mkt. cap
14.06B
Avg. vol.
1.15M
Volume
1.50M
P/E ratio
20.28
52-wk high
$186.12
52-wk low
$122.14
EPS
$6.82
Beta
0.38
Shares outstanding
101.65M
No. of employees
2K
News stories
From web sources and news partners
Investing.com
·
11 hours ago
UBS cuts Neurocrine Biosciences stock price target to $214 on competition
StreetInsider
·
12 hours ago
Neurocrine Bio. (NBIX) PT Lowered to $214 at UBS, Buy Rating Maintained
Simply Wall Street
·
22 hours ago
Neurocrine Biosciences (NBIX) Could Be 34% Undervalued After Its CMO Return
TipRanks
·
1 day ago
Neurocrine Names Eiry Roberts as New Chief Medical Officer
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2.5K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com